A case of autoimmune myositis after treatment with alemtuzumab for multiple sclerosis
{{output}}
Alemtuzumab is a high-efficacy disease-modifying therapy for the treatment of relapsing forms of multiple sclerosis and is associated with secondary autoimmune adverse events. We report a novel case of secondary autoimmune myositis that occurred seven months a... ...
